Prøve GULL - Gratis
Why are global markets so complacent?
Business Standard
|October 26, 2024
The world is beset with risks - political, geo-political, fiscal and monetary. But markets choose to look the other way, either being blissfully oblivious or wantonly negligent
Equity markets around the world continue to be on a tear. The MSCI Global Equity Index is close to its lifetime highs, up a staggering 30 per cent over the last year. But it is not just equities; all asset classes have thrived in recent months.
Yields may have backed up in recent weeks but United States rates are still pricing in lots of Federal Reserve cuts over the next year. And credit spreads remain very modest. So financial conditions in the US are very benign and have gotten progressively easier as reflected, for example, in the Chicago Fed's Financial Conditions Index.
This buoyancy is not limited to advanced economies. Emerging Market (EM) equities are also up almost 25 per cent over the last year and many EM currencies have rallied against the dollar over the last three months.
But why should we be surprised? Isn't the US firmly on its way to a soft landing? Or perhaps, no landing at all, given the sheer resilience of US growth? Hasn't China finally pulled out all the stops to jumpstart growth? Isn't the Fed in the midst of a large cutting cycle that will induce EM central banks to cut in tandem? In short, aren't we in macroeconomic "Goldilocks" land?
Or, are we? A more sober assessment of the data suggests the enthusiasm of global markets sits uneasily with a more uncomfortable economic reality that is peppered with a litany of political, geopolitical, fiscal and monetary risks.
To be clear, US growth has been resilient beyond expectation. Defying all forecasts, gross domestic product (GDP) growth is remarkably on track to print close to 3 per cent again this year. Prima facie, this is good news for the economy and equity markets, but it risks making the last mile of disinflation harder.
Denne historien er fra October 26, 2024-utgaven av Business Standard.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Business Standard
Business Standard
Labour Codes impact: HCL tech profit slips 11%
Q3 top line beats Street estimates, bottom line misses expectations
2 mins
January 13, 2026
Business Standard
New labour Codes, restructuring weigh on TCS earnings
Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.
1 min
January 13, 2026
Business Standard
Black drives the thrill for car buyers
Sees a surge in yearly sales, while white remains practical 'utility king'
2 mins
January 13, 2026
Business Standard
CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS
Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be
2 mins
January 13, 2026
Business Standard
China’s PVC rethink to help India pipe makers
Supply likely to tighten after S-PVC rebate withdrawal
2 mins
January 13, 2026
Business Standard
Responsible growth
India must ensure data centres are sustainable
2 mins
January 13, 2026
Business Standard
India’s GenZ is full of creativity: PM
Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.
1 min
January 13, 2026
Business Standard
Iran wants to negotiate after threats to attack, says Trump
At least 572 killed in protests; Tehran says situation ‘under full control’
2 mins
January 13, 2026
Business Standard
Insurers knock on Irdai door for clarity on director overlap ban
CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY
2 mins
January 13, 2026
Business Standard
Delhi HC allows Zydus to sell generic version of cancer drug
Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.
1 min
January 13, 2026
Listen
Translate
Change font size
